spacer
home > > summer 2009 > risk management: the route to safety
PUBLICATIONS


Risk Management: The Route to Safety

According to the European Medicines Agency (EMEA), there were 57 marketing authorisation withdrawals and suspensions for medicinal products for human use between 2000 and 2008. In 2008 alone, 12 products were withdrawn. This should be a clear sign of the need to improve the safety assessment of a new chemical entity (NCE) as early as possible during the development process.

The first step towards the development of safer drugs occurs at the pre-marketing stage. Preclinical data and, more importantly, clinical data are used to obtain an initial understanding of the riskbenefit profile of an NCE. In recent years, although there has been an increasing amount of regulation aimed at improving the quality of clinical research, this was initially focused on data quality and the appropriate assessment of efficacy. However, the assessment of safety came further into focus after the withdrawals of Baycol and Vioxx. Yet, despite this increased emphasis, drug safety and pharmacovigilance are typically still viewed as activities that are best conducted on large data pools that are only available once the drug is marketed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Peter Schüler, MD, is board certified in Neurology and in Pharmaceutical Medicine. After eight years in basic and clinical CNS research at a neurological university hospital, he joined Pharmacia in 1995. As Head of Medical Affairs, CNS, he oversaw all CNS compounds marketed by Pharmacia in Germany. In October 2000, he moved into the CRO business. In October 2007, Peter took over the position of VP Medical Affairs & Drug Safety at ICON, overseeing more than 150 safety experts and physicians in Europe and Asia. He lectures in Pharmaceutical Medicine at the University of Duisberg/Essen as Head Lecturer.
spacer
Peter Schüler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SGD Pharma introduces Ensiemo, the new complete child-resistant packaging solution for CBD oils

SGD Pharma today announces the launch of its new full packaging solution dedicated to the cannabidiol (CBD) oil market. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed Ensiemo – a glass dropper and bottle offering that meets international regulatory standards.
More info >>

White Papers

Advances in Aseptic Blow-Fill-Seal Processing of Pharmaceutical Liquids Improve Product Integrity and Patient Safety

Weiler Engineering, Inc

The latest improvements in aseptic blow-fill-seal technology are providing more streamlined automation of critical B/F/S processing areas, while limiting human intervention and effectively reducing airborne microbial bioburden and particulate levels, and enhancing sterility assurance and patient safety.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement